Michael Poch

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial”.

Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial

The Journal of Urology(2024)10.1097/ju.0000000000004020

N/A

1.6DataRank · unranked

77 citations

Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella +35 more

Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease

JNCI Journal of the National Cancer Institute(2022)10.1093/jnci/djac162

N/A

1.1DataRank · unranked

24 citations

G. Daniel Grass, Javier F. Torres–Roca, Peter A.S. Johnstone, Julio M. Pow‐Sang, Jasreman Dhillon +27 more

191 Targeting myeloid-derived suppressor cells (MDSCs) in bladder cancer to enhance efficacy of adoptive cell therapy (ACT)

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0191

N/A

0DataRank · unranked

0 citations

Brittany Bunch, Jamie Blauvelt, Annick Landin, Johannes Ali, Dominique Abrahams +5 more

Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer

Frontiers in Immunology(2023)10.3389/fimmu.2023.1275375

N/A

0DataRank · unranked

23 citations

Brittany Bunch, Awino Maureiq E. Ojwang’, Jamie Blauvelt, Annick Landin, Johannes Ali +8 more

345 Targeting acidity in bladder cancer to enhance efficacy of adoptive cell therapy (ACT) with tumor reactive T cells

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0345

N/A

0DataRank · unranked

0 citations

Jamie Blauvelt, Amy Hall, Matthew Beatty, Michael Poch, Katarzyna A. Rejniak +2 more

PD60-12 DISCRETIONARY AND NECESSARY READMISSION AFTER RADICAL CYSTECTOMY

The Journal of Urology(2020)10.1097/ju.0000000000000977.012

N/A

0DataRank · unranked

0 citations

Salim Cheriyan, Richard R. Reich, Ali Hajiran, Logan Zemp, Michael Poch +7 more

PETIL: Predicting Expansion of Tumor Infiltrating Lymphocytes for the Adoptive Cell Immunotherapy in Bladder Cancers

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.10.15.682695

N/A

0DataRank · unranked

0 citations

Ahmet Murat Aydın, Sarah Bazargan, Brittany Bunch, Ibrahim Chamseddine, Aleksandra Karolak +5 more

Preliminary results from phase Ib/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4574

N/A

0DataRank · unranked

3 citations

Philippe E. Spiess, Wade J. Sexton, Scott M. Gilbert, Michael Poch, Julio M. Pow‐Sang +11 more